Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by PoorOpinionon Oct 03, 2018 3:07pm
117 Views
Post# 28739658

RE:RE:RE:RE:Tomorrow

RE:RE:RE:RE:Tomorrow
bigd1986 wrote: along with sales i would like to get a firmer grip on # of patiens and more importantly the month over month % increase so we can extrapolate into the future. hearing that patient #s are increasing monthly would provide comfort and hopefully get analysts to revise their targets. the RBC dude will have to make a big adjustment (hopefully) if he realized his patient figures are no where near realistic. 


Most of the payors allow prescriptions for the first 6 months and renewal is dependant on clinical improvements. We are right on the cusp of the first patients getting to that renewal stage. I expect we won't hear anything about that this time around ( maybe next Q).

Renewal rate. Another thing for the pessimists and optimists to worry about or not.

Bullboard Posts